scholarly journals Monetary reinforcement for self‐monitoring of blood glucose among young people with type 1 diabetes: evaluating effects on psychosocial functioning

2019 ◽  
Vol 37 (4) ◽  
pp. 665-673
Author(s):  
J. J. Wong ◽  
A. Addala ◽  
D. Naranjo ◽  
K. K. Hood ◽  
E. Cengiz ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Young People ◽  
Psychosocial Functioning ◽  
Self Monitoring ◽  
Monetary Reinforcement

scholarly journals Factors Associated with Adherence to Self-Monitoring of Blood Glucose Among Young People with Type 1 Diabetes in China: A Cross-Sectional Study

2021 ◽  
Vol Volume 15 ◽  
pp. 2809-2819
Author(s):  
Wencong Lv ◽  
Jiaxin Luo ◽  
Qing Long ◽  
Jundi Yang ◽  
Xin Wang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Young People ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Self Monitoring ◽  
Factors Associated

Accuracy of Blood Glucose Meters for Self-Monitoring Affects Glucose Control and Hypoglycemia Rate in Children and Adolescents with Type 1 Diabetes

2015 ◽  
Vol 17 (4) ◽  
pp. 275-282 ◽  
Author(s):  
Claudia Boettcher ◽  
Axel Dost ◽  
Stefan A. Wudy ◽  
Marion Flechtner-Mors ◽  
Martin Borkenstein ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Children And Adolescents ◽  
Glucose Control ◽  
Self Monitoring

scholarly journals Use of Ecological Momentary Assessment to Measure Self-Monitoring of Blood Glucose Adherence in Youth With Type 1 Diabetes

2020 ◽  
Vol 33 (3) ◽  
pp. 280-289 ◽  
Author(s):  
Jennifer L. Warnick ◽  
Sarah C. Westen ◽  
Anastasia Albanese-O’Neill ◽  
Stephanie L. Filipp ◽  
Desmond Schatz ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Ecological Momentary Assessment ◽  
Self Monitoring ◽  
Ecological Momentary ◽  
Momentary Assessment

scholarly journals Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.

Diabetes Care ◽  
2020 ◽  
Vol 43 (10) ◽  
pp. 2411-2417 ◽  
Author(s):  
Stéphane Roze ◽  
John Isitt ◽  
Jayne Smith-Palmer ◽  
Mehdi Javanbakht ◽  
Peter Lynch
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Cost Effectiveness ◽  
Real Time ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Self Monitoring

scholarly journals Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden

2017 ◽  
Vol 5 (1) ◽  
pp. e000342 ◽  
Author(s):  
Peter Moström ◽  
Elsa Ahlén ◽  
Henrik Imberg ◽  
Per-Olof Hansson ◽  
Marcus Lind
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Self Monitoring

Frequency and motives of blood glucose self-monitoring in type 1 diabetes

2009 ◽  
Vol 85 (2) ◽  
pp. 183-188 ◽  
Author(s):  
M.V. Hansen ◽  
U. Pedersen-Bjergaard ◽  
S.R. Heller ◽  
T.M. Wallace ◽  
Å.K. Rasmussen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Self Monitoring ◽  
Blood Glucose Self Monitoring

scholarly journals The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)

2020 ◽  
Author(s):  
Shilan Seyed Ahmadi ◽  
Klara Westman ◽  
Aldina Pivodic ◽  
Arndís F Ólafsdóttir ◽  
Sofia Dahlqvist ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Conventional Therapy ◽  
Self Monitoring ◽  
Glucose Levels ◽  
Daily Insulin ◽  
Multiple Daily Insulin Injections ◽  
Mean Glucose ◽  
Hba1c Levels

<b><i>Objective: </i></b>According to recent guidelines, individuals with type 1 diabetes should spend less than 4.0% per day with glucose levels <3.9 mmol/L (<70 mg/dL) and less than 1.0% per day <3.0 mmol/L (<54 mg/dL). <p><b><i><br> Research methods: </i></b>In the GOLD randomised cross-over trial, 161 individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) were randomised to Continuous Glucose Monitoring (CGM) or conventional therapy with self-monitoring of blood glucose (SMBG) and evaluated over 16 months. We estimated the association between time spent in hypoglycaemia and various mean glucose and HbA1c levels.</p> <p> </p> <p><b><i>Results: </i></b>Time spent in hypoglycaemia (<3.9 mmol/L and <3.0 mmol/L) increased significantly with lower mean HbA1c and mean glucose levels during both CGM and conventional therapy. During CGM, 24 (57.1%) individuals with HbA1c <7.5 % (<58 mmol/mol) had <1.0% time spent in hypoglycaemia <3.0 mmol/L and 23 (54.8%) had <4.0% time spent in hypoglycaemia <3.9 mmol/L. During CGM, mean time spent in hypoglycaemia for individuals with mean HbA1c 7.0% (52 mmol/mol) was estimated to be 5.4% for <3.9 mmol/L and 1.5% for <3.0 mmol/L. The corresponding values during SMBG were 9.2% and 3.5%, respectively. Individuals with mean glucose levels of 8 mmol/L spent 4.9% more time with glucose levels <3.9 mmol/L and 2.8% more time <3.0 mmol/L during SMBG compared with CGM.</p> <p> </p> <p><b><i>Conclusions: </i></b>Reaching current targets for time in hypoglycaemia and at the same time HbA1c targets is challenging for type 1 diabetes patients treated with MDI both with CGM and SMBG monitoring. However, CGM is associated with considerably less time in hypoglycaemia than SMBG at a broad range of HbA1c levels and is crucial for patients with MDI treatment to have a chance to approach hypoglycaemia targets.</p>

scholarly journals The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)

2020 ◽  
Author(s):  
Shilan Seyed Ahmadi ◽  
Klara Westman ◽  
Aldina Pivodic ◽  
Arndís F Ólafsdóttir ◽  
Sofia Dahlqvist ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Conventional Therapy ◽  
Self Monitoring ◽  
Glucose Levels ◽  
Daily Insulin ◽  
Multiple Daily Insulin Injections ◽  
Mean Glucose ◽  
Hba1c Levels

<b><i>Objective: </i></b>According to recent guidelines, individuals with type 1 diabetes should spend less than 4.0% per day with glucose levels <3.9 mmol/L (<70 mg/dL) and less than 1.0% per day <3.0 mmol/L (<54 mg/dL). <p><b><i><br> Research methods: </i></b>In the GOLD randomised cross-over trial, 161 individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) were randomised to Continuous Glucose Monitoring (CGM) or conventional therapy with self-monitoring of blood glucose (SMBG) and evaluated over 16 months. We estimated the association between time spent in hypoglycaemia and various mean glucose and HbA1c levels.</p> <p> </p> <p><b><i>Results: </i></b>Time spent in hypoglycaemia (<3.9 mmol/L and <3.0 mmol/L) increased significantly with lower mean HbA1c and mean glucose levels during both CGM and conventional therapy. During CGM, 24 (57.1%) individuals with HbA1c <7.5 % (<58 mmol/mol) had <1.0% time spent in hypoglycaemia <3.0 mmol/L and 23 (54.8%) had <4.0% time spent in hypoglycaemia <3.9 mmol/L. During CGM, mean time spent in hypoglycaemia for individuals with mean HbA1c 7.0% (52 mmol/mol) was estimated to be 5.4% for <3.9 mmol/L and 1.5% for <3.0 mmol/L. The corresponding values during SMBG were 9.2% and 3.5%, respectively. Individuals with mean glucose levels of 8 mmol/L spent 4.9% more time with glucose levels <3.9 mmol/L and 2.8% more time <3.0 mmol/L during SMBG compared with CGM.</p> <p> </p> <p><b><i>Conclusions: </i></b>Reaching current targets for time in hypoglycaemia and at the same time HbA1c targets is challenging for type 1 diabetes patients treated with MDI both with CGM and SMBG monitoring. However, CGM is associated with considerably less time in hypoglycaemia than SMBG at a broad range of HbA1c levels and is crucial for patients with MDI treatment to have a chance to approach hypoglycaemia targets.</p>

Sign in / Sign up

Export Citation Format

Share Document